Catalyst Biosciences (CBIO) & its Peers Financial Review
Catalyst Biosciences (NASDAQ: CBIO) is one of 44 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it compare to its rivals? We will compare Catalyst Biosciences to similar businesses based off the strength of its analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.
Valuation and Earnings
This table compares Catalyst Biosciences and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Catalyst Biosciences||$561,999.00||-$19.79 million||-0.20|
|Catalyst Biosciences Competitors||$597.29 million||$249.71 million||-6.87|
Catalyst Biosciences’ rivals have higher revenue and earnings than Catalyst Biosciences. Catalyst Biosciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently the more expensive than other companies in its industry.
This table compares Catalyst Biosciences and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Catalyst Biosciences Competitors||-13,210.46%||-0.03%||-30.64%|
Insider and Institutional Ownership
29.2% of Catalyst Biosciences shares are owned by institutional investors. Comparatively, 45.3% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 5.0% of Catalyst Biosciences shares are owned by insiders. Comparatively, 13.9% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This is a breakdown of recent recommendations for Catalyst Biosciences and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Catalyst Biosciences Competitors||187||889||1662||65||2.57|
Catalyst Biosciences presently has a consensus target price of $24.50, indicating a potential upside of 592.09%. All “Biopharmaceuticals” companies have a potential downside of 1.69%. Given Catalyst Biosciences’ stronger consensus rating and higher probable upside, research analysts clearly believe Catalyst Biosciences is more favorable than its rivals.
Risk & Volatility
Catalyst Biosciences has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, Catalyst Biosciences’ rivals have a beta of 1.30, meaning that their average share price is 30% more volatile than the S&P 500.
Catalyst Biosciences rivals beat Catalyst Biosciences on 7 of the 12 factors compared.
About Catalyst Biosciences
Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.
Receive News & Ratings for Catalyst Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.